Prevalence of Iron Deficiency and Iron Deficiency Anemia in Exclusively Breastfed Term Infants in a Tertiary Hospital in Thailand Using the WHO Revised Criteria for Anemia


Wipawee Kaewkong, M.D.1, Pat Rojmahamongkol, M.D.2,*

1Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, 2Division of Developmental and Behavioral Pediatrics, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.



*Corresponding author: Pat Rojmahamongkol E-mail: patojung@yahoo.com

Received 9 February 2026 Revised 7 April 2026 Accepted 7 April 2026 ORCID ID: http://orcid.org/0000-0003-3853-0026 https://doi.org/10.33192/smj.v78i6.280298


All material is licensed under terms of the Creative Commons Attribution 4.0 International (CC-BY-NC-ND 4.0) license unless otherwise stated.


ABSTRACT

Objective: To assess the prevalence and associated factors of iron deficiency (ID) and iron deficiency anemia (IDA) in term exclusively breastfed (EBF) infants using the new 2024 Hb cutoff, and to study iron supplementation in Thai pediatricians’ clinical practice.

Materials and Methods: A retrospective chart review included healthy term EBF infants for ≥ 6 months from January 2014 to July 2022. Blood samples collected between 6 and 12 months were analyzed for CBC and serum ferritin (SF) levels. IDA was defined as Hb level < 10.5 g/dL and SF < 12 ng/ml, and ID was defined when SF < 12 ng/ml but Hb ≥ 10.5 g/dL.

Results: Of the 204 participants, 59.8% were female and mean age at blood collection was 9.4 months. Using 2024 criteria for anemia, the prevalence of ID and IDA was 11.3% and 10.3%, respectively. Daily iron supplementation was provided to 10.3% of infants, with the median dose of 1.23 mg/kg/day. No statistically significant risk factors (sex, birth order, birth weight, maternal age, numbers of maternal underlying conditions, receiving iron supplementation, liver paste consumption after age 6 months, and growth status) for ID or IDA were identified. Supplemented infants had significantly higher levels of Hb and SF.

Conclusions: Using the new criteria, ID and IDA are still prevalent. Most pediatricians do not routinely prescribe iron medication for EBF infants. Supplemented infants demonstrated more favorable Hb and SF levels. The potential role of iron supplementation to prevent ID and IDA during infancy in resource-limited countries should be emphasized.

Keywords: Iron deficiency; iron deficiency anemia; exclusive breastfeeding; exclusively breastfed infant; iron supplementation (Siriraj Med J 2026;78(6):402-412)


INTRODUCTION

Anemia is a significant global public health issue, particularly affecting adolescent girls, pregnant women, and children in low and middle-income countries. According to the World Health Organization (WHO) estimates, 40% (269 million) of children aged 6 to 59 months were anemic, with South East Asia and Africa being the most affected.1

Iron deficiency (ID) is a condition when iron storage is inadequate to preserve daily physiological activities. Iron deficiency anemia (IDA) is an anemia that results from ID. ID and IDA remain significant global health concerns. IDA is a prevalent cause of anemia, affecting 33.3% of 6-month-old children,2 however, ID without anemia, which has a prevalence of 40.5%,2 is an even greater concern as it may negatively impact the long-term neurodevelopment and behavior of children. Research shows that ID frequently coexists with attention-deficit/ hyperactivity disorder and autism spectrum disorder.3 Term infants are typically born with adequate iron reserves until 4 to 6 months of age.4 It is concluded that the slight quantity of iron in human milk (0.27 mg/day) is enough for the exclusively breastfed (EBF) infant.4 The American Academy of Pediatrics (AAP) recommends exclusive breastfeeding for at least 4 months, ideally 6 months.4 However, breastfeeding beyond 6 months without iron supplementation increases the risk of IDA by 9 months.5

To prevent IDA, the AAP has recommended 1 mg/kg/ day of iron supplementation starting at 4 months of age for EBF term infants, continuing until the beginning of appropriate iron-rich complementary foods consumption.4 However, universal iron medication supplementation to EBF infants may be difficult for some resource-limited countries including Thailand.

Previous studies in Thai infants revealed that the prevalence of IDA was significantly higher in breastfed infants compared to the iron-fortified formula-fed ones, and the risk factors for IDA included the infants who were breastfed, consumed insufficient complementary food, and had a history of low birth weight.6 Among Thai toddlers aged 12 to 36 months, the prevalence of ID was 15.44% when defined by a serum ferritin (SF) level below 12 ng/ml and 61.03% when defined by an SF level below 30 ng/ml.7 This variation in the cutoffs was attributed to the retrospective character of the study, which limited the collection of detailed health information about the population. Consequently, a higher cutoff was applied to individuals with infection or inflammation. Previous studies have also demonstrated that regular iron supplementation increased SF levels.5,7

Although Thai 2014 national policy recommends iron supplementation for 6 to 24-month-old children who do not consume iron-fortified milk or iron-rich food,8 specific iron supplementation protocols for EBF

infants are lacking, and data regarding Thai pediatric clinical practice in providing the supplementation for these infants are negligible. The updated 2021 Thai national recommendation highlights the immediate introduction of iron-rich complementary food as soon as the child reaches 6 months of age,9 along with providing an example of iron-containing food, which includes ≥ 3 tablespoonfuls of liver paste a week.10 According to the updated 2024 WHO guideline, children 6 to 23 months of age whose hemoglobin (Hb) level < 10.5 g/dL, which was changed from 11 g/dL of the 2011 cutoff11, and SF < 12 ng/ml were classified as IDA, while the ones whose SF

< 12 ng/ml but Hb ≥ 10.5 g/dL were classified as ID.1,12 The revised cutoff of 10.5 g/dL for infants 6–23 months aligns with recent global information regarding the 5th percentile of Hb distribution in this age group. This threshold was selected to optimize the balance between sensitivity and specificity in anemia screening while mitigating the potential risks associated with excessive iron intake, particularly in malaria-endemic regions or areas with a high prevalence of hemoglobinopathies.1,13 The prevalence of IDA in Thai EBF infants under

age 2 years in Thailand was 25.7% when using the earlier version of WHO cutoff.6 However, after the new Hb cutoff criteria were launched, data on the prevalence of IDA and ID in these infants also need to be updated. A recently published prospective study of Thai EBF infants when iron supplementation was given at 4 months of age demonstrated that the prevalence of IDA at 9 months old, using the WHO 2024 guideline for the Hb level cutoff for anemia was 6.4%,14 which was a promising result of iron medication. To confirm the benefit of iron supplementation for IDA prophylaxis in Thai EBF infants, which could serve as a basis for developing iron supplementation guidelines, it is essential to compare this to the prevalence in EBF infants who did not receive iron supplementation using the same Hb cutoffs. A retrospective analysis is an effective way to acquire a large sample size from previous clinical practice when iron supplementation was not well implemented.

To fill the information gaps, we retrospectively reviewed data of infants who were EBF for at least 6 months and underwent complete blood count (CBC) and ferritin level screening between 6 and 12 months of age. The objectives were (1) to ascertain the prevalence of IDA and ID in EBF infants applying the 2024 WHO Hb cutoff criteria for anemia diagnosis and compare this prevalence with the previous study in Thailand when iron supplement was given to all EBF infants at age 4 months and the 2024 Hb cutoffs was applied, (2) to identify factors associated with IDA and ID in this

population, and (3) to study the clinical practice of pediatricians regarding iron supplementation in EBF infants. IDA was defined as Hb level < 10.5 g/dL and serum ferritin < 12 ng/ml, and ID was described when serum ferritin < 12 ng/ml but Hb ≥ 10.5 g/dL.1,12 We hypothesized that the prevalence of IDA in Thai EBF infants using the new 2024 WHO cutoff Hb criteria (< 10.5 g/dL) would be higher than the 6.4% prevalence when iron supplement was given using the same 2024 cutoffs. Not receiving iron supplementation would be risk factor for ID and IDA in these infants, and most pediatricians routinely prescribed iron supplement to EBF infants.


MATERIALS AND METHODS

This study was approved by the Institution’s Ethics Committee for Human Research Protection (COA No. Si 513/2024). A retrospective chart review of healthy infants who visited the well-baby clinic for vaccination from January 2014 to July 2022 was conducted.

Sample size calculation

The sample size computation to evaluate the prevalence based on the prior study that reported a 25.7% prevalence of IDA in EBF infants.6 With a 95% confidence level and a 5% acceptable error, the sample size needed in this study was at the minimum of 204.

Study population

Inclusion criteria were singleton term infants whose birth weight was at least 2,500 grams who were reported by caregivers as being EBF until 6 months of age, and underwent complete blood count (CBC) and SF testing between 6–12 months of age as routine anemia screening at well-baby clinic. This study defined EBF infants as those whose vaccination visit medical records at 6 months included terms such as “exclusive breastfeeding”, “consumed only breast milk or breastfeeding or expressed breast milk”. Those who were diagnosed with anemia or IDA, had a history of blood transfusion, previously received iron supplementation ≥ 4 mg/kg/day before CBC and SF tests, as well as those with underlying diseases, such as cyanotic heart disease, thalassemia, or red blood cell membrane defects, were excluded from the study.

The CBC testing required 2 mL of venous blood in a K2-EDTA tube. The analysis was done using SLS-hemoglobin method by automated Sysmex XN-3000 and XN-9000 analyzers. The ferritin testing required 4-6 mL of venous blood in lithium heparin tube. The analysis was done using Electrochemiluminescence (ECLIA)/ Sandwich principle.

Data collection

- Laboratory data included Hb and SF levels performed between 6 and 12 months of age.

Outcome

The principal outcomes of this study were the number of infants who were categorized as ID and IDA when using WHO updated criteria, the number of infants who were prescribed iron medication, including dose and duration of the medication the child took, the association between factors and ID, and IDA, as well as differences in laboratory findings between the supplemented and non-supplemented groups.

Statistical analysis

The IBM SPSS Statistics 22 software package was used for statistical analysis. Demographic characteristics were analyzed using descriptive statistics. Categorical data were presented as percentages. Continuous data were presented as the mean with SD for normally distributed variables and as the median with range for nonnormally distributed variables. The associations between the infants’ sex, birth order, birth weight for gestational age status, history of receiving iron supplementation, infant’s liver paste consumption after age 6 months, growth status at the day of blood testing, maternal age and numbers

of maternal underlying conditions; and ID and IDA were evaluated using the Chi-square test. Moreover, the association between all of the aforementioned factors and ID and IDA were analyzed using both univariate analysis and multivariable logistic regression. The multivariable logistic regression was examined by using enter, forward, backward, and stepwise methods. The association between maternal underlying diabetes mellitus, and hypertension and ID and IDA were analyzed using the Fisher’s exact test. Significant differences in mean Hb and median SF between the iron-supplemented and non-supplemented groups were analyzed using the Student’s t-test and Mann-Whitney U test, respectively. Spearman’s correlations were applied to evaluate the relationship between laboratory results (mean Hb level, median SF) and the dosage and duration of iron supplementation. A p-value of less than

0.05 was considered statistically significant.

RESULTS

During the study period, 610 healthy infants attended the well-baby clinic and underwent blood tests for Hb and SF between 6 and 12 months of age. Of these, 233 singleton term infants were EBF. Twenty-nine (12.4%) were excluded because 17 had a history of low birth weight (<2500 g), five were diagnosed with IDA and received iron medication treatment (≥ 4 mg/kg/day) before the blood tests, four were diagnosed with hemoglobinopathy and three were diagnosed with red blood cell membrane defects. A total of 204 remained for final analysis.

The chart review of these 204 infants was completed. Their demographic data are presented in Table 1. Most participants (59.8%) were female, were born with appropriate for gestational age (93.6%), and had normal growth parameter at the day of blood testing (85.8%). Mean age at blood collection was 9.4 months with the SD of 0.9 months. After applying a cutoff Hb level of <10.5 g/dL, 21 of 204 (10.3%) are classified as IDA, while 23 (11.3%) are classified as ID. Twenty-one (10.3%) of these 204 EBF infants were prescribed daily iron supplementation. The dose of elemental iron ranged from 0.92 to 3.1 mg/ kg/day, with a median daily dose of 1.23 mg/kg. Iron supplementation was initiated at the infants’ median age of 189 days, ranging from 40 to 290 days. The duration of supplementation before blood testing ranged from 21 to 140 days, with a median duration of 70 days. For the 21 infants who received iron supplementation, one (4.8%) had IDA and none developed ID. No significant associations were identified among the analyzed factors between iron-deficiency anemic infants and non-anemic infants, or between iron-deficient and iron-sufficient infants (Table 2). Neither univariate analysis nor multivariable


TABLE 1. Demographic characteristics of 204 exclusively breastfed infants.


Characteristics

Number

Percentage

Sex



Male

82

40.2

Female

122

59.8

Birth order



First born

118

57.8

Second born or more

86

42.2

BW for GA status (n = 190)

SGA

6

3.2

AGA

178

93.6

LGA

6

3.2

Maternal age



< 35 years

123

60.3

≥ 35 years

81

39.7

Numbers of maternal underlying conditions (n = 182)

No underlying disease

116

63.7

With underlying disease

66

36.3

1 underlying disease

54

81.8

2 underlying diseases

10

15.2

3 underlying diseases

2

3.0

Types of maternal underlying conditions (n = 66)

Diabetes mellitus

30

45.5

Hypertension

5

7.6

Thalassemia trait

28

42.4

Thalassemia diseases

5

7.6

Others*

12

18.2

Iron supplement



Iron supplement

21

10.3

No iron supplement

183

89.7

Consuming liver paste after 6 months of age (n = 115)

Yes

93

80.9

No

22

19.1

Growth categories**

Wasted

4

2.0

Normal

175

85.8

Possible risk of overweight

24

11.7

Overweight

1

0.5



BW: Birth weight, GA: Gestational age, SGA: Small for gestational age, AGA: Appropriate for gestational age, LGA: Large for gestational age

* Other maternal underlying conditions included epilepsy, hepatitis B infection, hepatitis B carrier, thyroid cancer, hyperthyroid, hypothyroid, and SLE.

** Growth categories were categorized according to WHO reference curves: “Wasted” was defined as weight-for-length was < -2SD, “normal” was defined as weight-for-length was -2SD to 1SD, “possible risk of overweight” was defined as weight-for-length was >1SD to 2SD), and “overweight” was defined as weight-for-length was >2SD to 3SD.


TABLE 2. Factors associated with iron deficiency and iron deficiency anemia analyzed by Chi-square tests.


Factor Iron deficiency (ID) Iron deficiency anemia (IDA)


ID

No ID

p-value

IDA

No IDA

p-value

Sex







Male

12 (14.6)

70 (85.4)

0.214

10 (12.2)

72 (87.8)

0.464

Female

11 (9.0)

111 (91.0)


11 (9.0)

111 (91.0)


Birth order







First born

15 (12.7)

103 (87.3)

0.447

12 (10.2)

106 (89.8)

0.945

Second born or more

8 (9.3)

78 (90.7)


9 (10.5)

77 (89.5)


BW for GA status (n = 190)







SGA

1 (16.7)

5 (83.3)

0.416

1 (16.7)

5 (83.3)

0.748

AGA

20 (11.2)

158 (88.8)


19 (10.7)

159 (89.3)


LGA

1 (16.7)

5 (83.3)


0 (0.0)

6 (100.0)


Maternal age







< 35 years

14 (11.4)

109 (88.6)

0.952

12 (9.8)

111 (90.2)

0.755

≥ 35 years

9 (11.1)

72 (88.9)


9 (11.1)

72 (88.9)


Numbers of maternal underlying conditions (n = 182)

No underlying disease

15 (12.9)

101 (87.1)

0.718

14 (12.1)

102 (87.93)

0.404

1 underlying disease

5 (9.3)

49 (90.7)


3 (5.6)

51 (94.4)


2 underlying diseases

2 (20.0)

8 (80.0)


2 (20.0)

8 (80.0)


3 underlying diseases

0 (0.0)

2 (100.0)


0 (0.0)

2 (100.0)


Iron supplement







Iron supplement

0 (0.0)

21 (100.0)

0.139

1 (4.8)

20 (95.2)

0.703

No iron supplement

23 (12.6)

160 (87.4)


20 (10.9)

163 (89.1)


Consuming liver paste after 6 months of age (n = 115)

Yes

10 (10.8)

83 (89.2)

0.466

12 (12.9)

81 (87.1)

0.314

No

4 (18.2)

18 (81.8)


5 (22.7)

17 (77.3)


Growth categories

Wasted

0 (0.0)

4 (100.0)

1.000

0 (0.0)

4 (100.0)

0.355

Normal

21 (12.0)

154 (88.0)


17 (9.7)

158 (90.3)


Possible risk of overweight

2 (8.3)

22 (91.7)


4 (16.7)

20 (83.3)


Overweight

0 (0.0)

1 (100.0)


0 (0.0)

1 (100.0)


Abbreviations: ID: Iron deficiency, IDA: Iron deficiency anemia, BW: Birth weight, GA: Gestational age, SGA: Small for gestational age, AGA: Appropriate for gestational age, LGA: Large for gestational age

logistic regression demonstrated statistically significant associations between the analyzed factors and ID and IDA. However, the history of receiving iron supplementation cannot be analyzed in multivariable logistic regression model due to the lack of variability in the outcome, which prevented the program from calculating the association. The Hb levels in this study follow a normal distribution,

with a mean of 11 g/dL and a SD of 0.07 g/dL. In contrast, SF levels follow a nonnormal distribution, with a median of 26.1 ng/ml and a range of 1.9 to 590.0 ng/ml. Laboratory values of Hb and SF, comparing between infants who received iron supplementation and those who did not, are shown in Table 3. Infants who received iron supplementation have significantly higher levels of Hb and SF. There is no statistically significant correlation between the dose and duration of supplementation and mean Hb and median SF levels (Table 4).


DISCUSSION

The present study demonstrates an 11.3% prevalence of ID, and a 10.3% prevalence of IDA in EBF infants when using the updated cutoff Hb level (<10.5 g/dL). No statistically significant associations were found between analyzed factors and ID and IDA. Small numbers of

pediatricians in this tertiary hospital were aware of iron supplementation in EBF infants as only 10.3% (21 out of 204) of the infants were prescribed the medication. Although this small number has low statistical power, the supplemented infants demonstrated promising findings regarding more favorable Hb and SF levels.

To our knowledge, this is the first study on the prevalence of IDA and ID, as well as the factors associated with these conditions in EBF infants using the 2024 WHO criteria in Thailand. Although there are no international studies on the prevalence of IDA and ID using the updated anemia criteria, the prevalence of IDA (10.3%) in this retrospective study is higher than the 6.4% in a previous Thai prospective cohort study using the same 2024 cutoff when iron medication supplementation was provided to all infants after 4 months of age.14 These findings emphasize the risk of IDA in EBF infants, particularly after six months of age, without adequate iron supplementation. Despite the assumption that human milk provides adequate iron for the first four to six months of life, the rapid growth and increasing iron demands16 of infants require timely dietary or supplemental iron interventions to maintain sufficient iron storage.

The prevalence of ID (11.3%) in this study is much


TABLE 3. Hemoglobin and serum ferritin levels of 204 infants categorized by history of receiving iron supplementation.


Laboratory

Iron supplemented n = 21

Non-iron supplemented n = 183


p-value

Mean Hemoglobin (g/dL) (SD)

11.5 (0.92)

11.0 (1.06)

0.040*

Median Serum ferritin (ng/ml) (min, max)

37.8 (9, 108)

23.5 (1.9, 590)

0.005*

*p-value <0.05





TABLE 4. Spearman correlation between laboratory results and the dosage and duration of iron supplementation.


Laboratory results

Correlation Coefficients

p-value

Dosage of iron supplementation (mg/kg/day)

Hemoglobin


-0.121


0.602

Serum ferritin

0.026

0.912

Duration of iron supplementation (days)

Hemoglobin


0.220


0.337

Serum ferritin

-0.060

0.795

less than in the previous Thai prospective cohort study which reported a prevalence of 36.2% after receiving iron supplementation.14 This difference may come from the incongruity of the laboratory diagnostic criteria for ID, i.e. the previous study used transferrin saturation, while this study uses serum ferritin level. Additionally, although the infants in this study were recruited from a well-baby clinic which was supposed to be healthy, we cannot guarantee that these infants were free from recent infections or inflammation that can falsely elevate their serum ferritin levels.

A cohort study conducted in Ghana, Honduras, Mexico, and Sweden among 404 EBF infants reports male sex as a key predictor of ID,17 in contrast, the current study did not observe the association. This may be because the previous study excluded infants with elevated concentrations of C-reactive protein (CRP), which is the marker of inflammation, while our study did not. One previous study also revealed that small-for-gestational-age infants had the highest risk for IDA.18 However, our study did not show any association between this factor and ID/IDA. This difference may result from different Hb cutoff level criteria, and small sample size of the infants who had small for gestational age in this study, which comprised only 3.5%.

The finding that none of the infants who received iron supplements developed ID, compared to 12.6% of those who did not (Table 2) was statistically insignificant. However, this information correlates with a previous study in Thailand that demonstrated a lower prevalence of ID in iron supplemented infants (40.9%) than in infants that did not receive supplementation (61.4%) using a cutoff of SF < 30 ng/ml.7 For IDA, this current study showed that only 4.8% of infants who received iron supplements developed this condition, while approximately 10.9% of those who did not receive iron supplements developed IDA. This is correlated with a randomized controlled study in Honduras that found higher prevalence of IDA at 9 months in the placebo group compared to the supplemented one (29% VS 9%).19 These current findings suggest that iron supplementation may be clinically beneficial, although it does not show statistical significance, which is possibly due to the small number (n=21) of infants prescribed the medication.

According to the 2021 Thai national guideline emphasis on iron-rich food and promoting liver paste, so infants’ consumption of liver paste after 6 months of age is one of our factors of interest. We did not find a significant association between this factor and ID/IDA. However, we did not know the amount consumed, the frequency, and the duration of liver intake. Moreover, we did not

collect data on whether pregnant mothers ingested iron supplements or consumed iron-rich foods, nor did we know if the children consumed other iron-rich foods. These factors may have acted as confounding variables, potentially obscuring any association between liver paste consumption and the occurrence of ID and IDA. However, as shown in Table 2, infants who consumed liver paste have lower rates of ID and IDA compared to those who did not (10.8% vs 18.2% for ID and 12.9% vs 22.7% for IDA). Data on liver paste consumption are missing for 89 of 204 infants (44%), which may limit the ability to detect a clinically significant relationship. Consequently, despite these trends, no statistical significance is observed. This study found that neither maternal diabetes nor hypertension was associated with IDA (p = 0.744, and 0.428 for diabetes, and hypertension, respectively) and ID (p = 0.371, and 1.000 for diabetes, and hypertension, respectively). These findings are contradictory with the recent review article which stated that maternal glucose intolerance and hypertension could threaten fetal iron storage,20 and high prevalence of ID without anemia (24%) and IDA (22%) at 6-12 months old infants of diabetic mothers,21 as well as high prevalence of anemia in the ones whose mother had gestational hypertension (6.78%, and 5.25% in 6-month-, and 12-month-old infants, respectively).22 The disparities could be due to the different criteria for diagnosis of IDA and ID. The previous study used SF and transferrin saturation, as well as Hb cutoff of 11 g/dL, while this current study did not use transferrin saturation, and used the Hb cutoff at 10.5 g/dL. The numbers of mothers with these underlying diseases in this study were much lower than the previous ones (5 VS 17,264 for maternal hypertension, and 30 VS

50 for maternal diabetes).

Laboratory findings indicate that infants receiving iron supplementation exhibit significantly higher SF levels compared to non-supplemented infants (37.8 ng/ ml vs. 23.5 ng/ml; p=0.005), however, the median SF levels in both groups are not categorized as indicative of ID (SF <12 ng/ml). The much smaller sample size in the supplemented group and the short duration (median 70 days) of supplementation, compared to the duration of 3-5 months in other studies,7,19 may limit the ability to detect associations between iron supplementation and ID/IDA, as well as the correlation between laboratory (Hb and SF levels) and the dosage and duration of iron supplementation. However, our findings align with international randomized controlled trials in EBF infants that demonstrated significantly higher SF and Hb levels in the iron-supplemented group.19,23 These findings underscore the importance of iron supplementation to improve in

hematologic outcomes. Although the association between iron supplementation in EBF infants and ID/IDA remains uncertain, we think that obstetricians should advise pregnant mothers to take iron supplements and consume iron-rich foods to increase the iron storage in their fetuses. Moreover, pediatricians should encourage the nursing mothers to start adequate iron-rich complementary food to their infants when the infants’ iron reserve is insufficiency at age 4-6 months.

Strengths and limitations

A notable strength of this study is its focal point on EBF infants, a population particularly at risk for ID and IDA, and using updated 2024 WHO cutoff Hb levels for anemia. Despite this risk, we continue to recommend exclusive breastfeeding for at least six months due to its nonnutritive benefits, such as enhancing immunity. This study provides insight into strategies for preventing ID and IDA during exclusive breastfeeding in Thailand which is one of resource-limited countries. These strategies include iron supplementation and the consumption of iron-rich food such as liver paste, red meat, and pork blood by both the infant and the pregnant mothers, as well as maintaining good compliance with iron supplementation. The findings of this study might be fundamental information for developing Thai national guideline for iron supplement in EBF infants.

This study has limitations. The sample size of 204 might not be able to detect the statistical significance of known predictors of infantile anemia, such as maternal age and maternal history of gestational diabetes and hypertension or eclampsia. Small sample size of supplemented infants (21 out of 204) reduced the statistical power to find the association with ID/IDA. The nature of retrospective design led to the tendency of information bias from inconsistent data documented in the medical records. Although a retrospective study design is useful for obtaining a large sample size from past clinical data to improve future clinical practice,24,25 retrospective data collection prevented us from gathering uncontrolled confounders for infant’s iron reserve, including the duration and amount of iron-rich complementary foods before the blood test, and the duration of exclusive breastfeeding, the temporal proximity of maternal repeated pregnancies, the information about infants’ birth ferritin and duration of cord clamping at birth. Another important confounder is postnatal growth rates which can influence the pace at which prenatal iron supplies are utilized to sustain the needs for growth. These confounders should be used to adjust for identify factors associated with ID/ IDA. However, these variables were not included in

our statistical analyses. Many data were missing. For example, 17 of 21 (81.0%) infants did not have data on medication compliance or the adverse effects of iron supplementation. We extracted data beginning from infants who had undergone CBC and SF testing, and then identified those who were EBF. Therefore, we do not have data on EBF infants who were not tested, which is another limitation of this study.

Although the participants had strong likelihood to be healthy as they came for vaccination visit, the lack of assessment for inflammation/infection or inflammatory markers, such as CRP, might hinder the identifying of the child’s underlying inflammation that could lead to an overestimation of serum ferritin levels, and result in underestimation of the prevalence of ID/IDA in this study. Future research should consider other hematologic marker that is not affected by body inflammatory process such as reticulocyte hemoglobin equivalent (RET-He) as an indicator of iron deficiency status.26 Reliance on a single-center population and the small proportion of infants receiving iron supplementation are also important limitations of this study. These limitations could affect the generalizability of the findings and decrease the statistical power required to detect associations.

Further studies should be randomized-controlled, involve a larger population, and include multicenter studies. Additionally, data on potential confounders of ID and IDA, such as interpregnancy interval, delayed cord clamping, neonatal ferritin level at delivery, as well as the pace of growth, the consumption of iron-rich foods, compliance with medication, and the side effects of iron supplementation in each infant, should also be collected.


CONCLUSION

Using the 2024 WHO guideline for the diagnosis of ID and IDA, this study measured an 11.3% prevalence of ID and a 10.3% prevalence of IDA among EBF term infants, emphasizing the importance of timely dietary and supplemental iron interventions for these infants. None of the analyzed factors were significantly associated with ID or IDA in this study. Most pediatricians in this single-center study did not routinely prescribe iron medication supplementation. Although the small sample size of the supplemented group, none of them developed ID, and they also demonstrated associations with more favorable levels of Hb and SF compared to their non-supplemented peers. While specific iron supplementation national protocols for Thai EBF infants are lacking, pediatricians should increase awareness of the risk of IDA and ID in these infants and consider iron medication

supplementation. These findings underscore the need for routine screening and education for caregivers to prevent ID and IDA during infancy. Further research, particularly with longitudinal and multicenter designs, is needed to explore the long-term implications of ID/ IDA and optimize preventive strategies, as well as to develop a Thai national policy to prevent ID and IDA in EBF infants.

Data Availability Statement

The data generated and/or analyzed during the study are available from the corresponding author on reasonable request.

ACKNOWLEDGEMENTS

The authors gratefully thank Asst. Prof. Sirinapa Siwarom, Division of Nutrition, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand, Assoc. Prof. Kamon Phuakpet, Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand, and Dr. Prakasit Wannapaschaiyong, Division of Developmental and Behavioral Pediatrics, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand for reviewing and giving recommendation for this manuscript, Miss Nerisa Thornsri and Miss Julaporn Pooliam and Dr. Sasima Tongsai, Siriraj Research Data Management Unit for assistance with statistical analysis, and Dr. Mark Simmerman, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand for English language editing.


DECLARATIONS

Grants and Funding Information

None.

Conflict of Interest

All authors declare no personal or professional conflicts of interest relating to any aspect of this study. This was an unfunded study.

Registration Number of Clinical Trial

This is a retrospective research and does not have registration number of clinical trial.

Author Contributions

Conceptualization and methodology, P.R.; Investigation, W.K.; Formal analysis, W.K. and P.R.; Visualization and writing – original draft, W.K.; Writing – review and

editing, P.R.; Supervision, P.R. All authors have read and agreed to the final version of the manuscript.

Use of Artificial Intelligence

There is no use of artificial intelligence-assisted technologies in the production of submitted work.

REFERENCES

  1. World Health Organization. Guideline on haemoglobin cutoffs to define anaemia in individuals and populations [Internet]. Geneva: World Health Organization; 2024 [cited 2024 Dec 1]. Available from: https://www.who.int/publications/i/item/ 9789240088542

  2. Varea A, Disalvo L, Fasano MV, Sala M, Avico AJ, Azrack MÁ, et al. Effectiveness of weekly and daily iron administration for the prevention of iron deficiency anemia in infants. Arch Argent Pediatr. 2023;121(4):e202202815.

  3. Pivina L, Semenova Y, Doşa MD, Dauletyarova M, Bjørklund G. Iron Deficiency, Cognitive functions, and neurobehavioral disorders in children. J Mol Neurosci. 2019;68(1):1-10.

  4. Baker RD, Greer FR. Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young children (0-3 years of age). Pediatrics. 2010;126(5):1040-50.

  5. Meinzen-Derr JK, Guerrero ML, Altaye M, Ortega-Gallegos H, Ruiz-Palacios GM, Morrow AL. Risk of infant anemia is associated with exclusive breast-feeding and maternal anemia in a Mexican cohort. J. Nutr. 2006;136(2):452-8.

  6. Tantracheewathorn S, Lohajaroensub S. Incidence and risk factors of iron deficiency anemia in term infants. J Med Assoc Thai. 2005;88(1):45-51.

  7. Chokviriyakorn N. Prevalence of and factors associated with iron deficiency among Thai toddlers aged 12 - 36 months in the well child clinic of Luang Pho Taweesak Hospital. Vajira Med J. 2017;61:43–54.

  8. Phuakpet K. Anemia screening. In: Guideline in Child Health Supervision [Internet]. Bangkok: The Royal College of Pediatricians of Thailand; 2014 [cited 2024 Dec 1]. Available from: http:// datahpc9.anamai.moph.go.th/group_sr/allfile/1612321975. pdf

  9. The Royal College of Pediatricians of Thailand. Guideline in Child Health Supervision [Internet]. Bangkok: The Royal College of Pediatricians of Thailand; 2021 [cited 2024 Dec 1]. Available from: https://drive.google.com/file/d/116EdUOc0TQaQLYr tlmRaff72PcS6DT-d/view

  10. Bureau of Nutrition, Department of Health, Ministry of Public Health. Mother and child health handbook [Internet]. Bangkok: Ministry of Public Health; 2023 [cited 2024 Dec 1]. Available from: https://www.hp.anamai.moph.go.th

  11. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity [Internet]. Geneva: World Health Organization; 2011 [cited 2024 Dec 1]. Available from: https://iris.who.int/handle/10665/85839

  12. World Health Organization. WHO guideline on use of ferritin concentration to assess iron status in individuals and populations [Internet]. Geneva: World Health Organization; 2020 [cited 2024 Dec 1]. Available from: https://www.who.int/publications/i/ item/9789240000124

  13. Braat S, Fielding KL, Han J, Jackson VE, Zaloumis S, Xu JXH, et al.

    Haemoglobin thresholds to define anaemia from age 6 months to 65 years: estimates from international data sources. Lancet Haematol. 2024;11(4):e253-e64.

  14. Sittimol A, Saengpanit P, Vatthana N, Rojmahamongkol P. Prevalence of iron deficiency anemia in exclusively breastfed infants after a 5-month iron supplementation. Sci Rep. 2024; 14(1):23924.

  15. Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr. 2013;13:59.

  16. De Onis M. World Health Organization Reference Curves. In: Frelut ML, editor. The ECOG’s eBook on Child and Adolescent Obesity [Internet]. European Childhood Obesity Group; 2015 [cited 2024 Dec 1]. Available from: https://ebook.ecog-obesity. eu/wp-content/uploads/2015/02/ECOG-Obesity-eBook-World-Health-Organization-Reference-Curves.pdf

  17. Yang Z, Lönnerdal B, Adu-Afarwuah S, Brown KH, Chaparro CM, Cohen RJ, et al. Prevalence and predictors of iron deficiency in fully breastfed infants at 6 mo of age: comparison of data from 6 studies. Am J Clin Nutr. 2009;89(5):1433-40.

  18. Sundararajan S, Rabe H. Prevention of iron deficiency anemia in infants and toddlers. Pediatr Res. 2021; 89(1):63–73.

  19. Domellöf M, Cohen RJ, Dewey KG, Hernell O, Rivera LL, Lönnerdal B. Iron supplementation of breast-fed Honduran and Swedish infants from 4 to 9 months of age. J Pediatr. 2001;138(5): 679-87.

  20. Georgieff MK. Maternal gestational iron status and infant

    haematological and neurodevelopmental outcomes. BJOC. 2023;130(Suppl 3):92-6.

  21. Engkakul P, Kositamongkol S. Prevalence of iron deficiency in infants of diabetic mothers at the age of 6 to 12 months. J Med Assoc Thai. 2020;103(12):1262-8.

  22. An H, Chen H, Li Z, Zhang L, Zhang Y, Liu J, et al. Association of gestational hypertension with anemia under 5 years old: two large longitudinal Chinese birth cohorts. Nutrients. 2022;14(8):1621.

  23. Nagpal J, Sachdev HP, Singh T, Mallika V. A randomized placebo-controlled trial of iron supplementation in breastfed young infants initiated on complementary feeding: effect on haematological status. J Health Popul Nutr. 2004;22(2):203-11.

  24. Khorwanichakij N, Kungwankiattichai S, Owattanapanich W. Validation of several formulas to differentiate thalassemia from iron deficiency anemia and proposal of a thalassemia-iron deficiency discrimination (TID) predictive score. Siriraj Med

    J. 2022;74(4):256-65.

  25. Sirichamratsakul K, Sangkhathat S, Chongsuvivatwong V. Referral patterns, co-occurring conditions and survival outcomes of biliary atresia in Thailand: Security Office Registry. Siriraj Med J. 2025;77(9):610-9.

  26. Sinlapamongkolkul P, Pusongchai T, Buaboonnum J, Satayasai W, Surapolchai P. Diagnostic utility of reticulocyte hemoglobin equivalent for identifying iron deficiency in hospitalized children in a thalassemia-endemic region: a single-center cross-sectional study. Siriraj Med J. 2026;78(1):68-78.